Skip to main content
Top
Published in: Drug Safety 2/2000

01-08-2000 | Review Article

A Survey on Factors that Could Affect Adverse Drug Reaction Reporting According to Hospital Pharmacists in Great Britain

Authors: Dimah Sweis, Dr Ian C.K. Wong

Published in: Drug Safety | Issue 2/2000

Login to get access

Abstract

Introduction: Since April 1997, UK hospital pharmacists have been invited to submit reports of suspected adverse drug reactions (ADRs) to the Committee on Safety of Medicines (CSM) and Medicines Control Agency. Three studies have investigated the involvement of hospital pharmacists in ADR reporting; however, they did not investigate the possible factors that could affect ADR reporting.
Objectives: (i) To analyse the extent to which hospital pharmacists think that specified factors could affect reporting ADRs; (ii) to identify any additional factors that could hinder reporting; and (iii) to recommend possible methods to improve reporting.
Methods: Piloted questionnaires were sent to 548 hospital pharmacists in Great Britain randomly selected by the Royal Pharmaceutical Society of Great Britain (RPSGB) from their computer database. 346 questionnaires were returned and 280 were included in this study.
Results: 46% of the pharmacists had identified ADRs that were considered to be reportable according to the CSM criteria in the 6 months prior to the survey. 39% did not report these ADRs either to the CSM or the manufacturers. Only 8.2% reported that their hospitals had a written policy; conversely, 73.7% agreed that such a policy could enhance ADR reporting. Although not statistically significant, the result showed an increasing tendency to report ADRs by pharmacists who had received training. Furthermore, there was an increasing tendency to report ADRs with increasing seniority.
Discussion: The results show that hospital pharmacists say they are more likely to report serious and rare ADRs and ADRs associated with newly marketed drugs. Factors that could reduce ADR reporting included being busy at work, lack of confidence in recognising ADRs and the fear of breaching patient confidentiality. Most common suggestions on methods to improve ADR reporting were to provide ADR training and meetings (34%) and a hospital written policy (24%).
Recommendations: ADR training and meetings would be a useful step in improving hospital pharmacist ADR reporting. Therefore, we recommend that the CSM and the RPSGB liaise with regional drug information centres and schools of pharmacy to provide more study days and training programmes for hospital pharmacists. Furthermore, the CSM should write to the ‘Drugs and Therapeutics Committee’ of each hospital and encourage them to develop a written local policy for pharmacist ADR reporting. Further studies should be conducted to test the recommendations noted here, assessing the response of the pharmacists in terms of absolute numbers of reports made. It would be particularly interesting to study the need for a written hospital policy and education.
Literature
1.
go back to reference Lazaron J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–5CrossRef Lazaron J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–5CrossRef
2.
go back to reference Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Clinical review. Adverse drug reactions. BMJ 1998; 316: 1295–8PubMedCrossRef Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Clinical review. Adverse drug reactions. BMJ 1998; 316: 1295–8PubMedCrossRef
3.
go back to reference Wong ICK. Pharmacovigilance resources in the United Kingdom. Pharm J 1999; 263: 285–8CrossRef Wong ICK. Pharmacovigilance resources in the United Kingdom. Pharm J 1999; 263: 285–8CrossRef
4.
go back to reference Smith J. Have your say in ADR reporting. Pharmacy in Practice 1997; 7 465 Smith J. Have your say in ADR reporting. Pharmacy in Practice 1997; 7 465
5.
6.
go back to reference Lee A, Bateman DN, Edwards C, et al. Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ 1997; 315: 519PubMedCrossRef Lee A, Bateman DN, Edwards C, et al. Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ 1997; 315: 519PubMedCrossRef
7.
go back to reference Anonymous. Pharmacist’s adverse drug reaction reporting to start on April 1. Pharm J 1998; 258: 330–1 Anonymous. Pharmacist’s adverse drug reaction reporting to start on April 1. Pharm J 1998; 258: 330–1
8.
go back to reference Green CF, Mottram DR, Rowe P, et al. An investigation into adverse drug reaction monitoring by United Kingdom hospital pharmacy departments. Int J Pharm Pract 1997; 5: 202–8CrossRef Green CF, Mottram DR, Rowe P, et al. An investigation into adverse drug reaction monitoring by United Kingdom hospital pharmacy departments. Int J Pharm Pract 1997; 5: 202–8CrossRef
9.
go back to reference Anonymous. Hospital pharmacist ‘Yellow Card’ reporting found to be ‘insufficiently developed’. Pharm J 1998; 261: 44 Anonymous. Hospital pharmacist ‘Yellow Card’ reporting found to be ‘insufficiently developed’. Pharm J 1998; 261: 44
10.
go back to reference Davis S, Coulson RA, Wood SM. Adverse drug reaction reporting by hospital pharmacists: the first year. Pharm J 1999; 262: 366–7 Davis S, Coulson RA, Wood SM. Adverse drug reaction reporting by hospital pharmacists: the first year. Pharm J 1999; 262: 366–7
11.
go back to reference Belton KJ, Lewis SC, Payne S, et al. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995; 39: 223–6PubMedCrossRef Belton KJ, Lewis SC, Payne S, et al. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995; 39: 223–6PubMedCrossRef
12.
go back to reference Talbot JC. Spontaneous reporting. In: Glaxo Research Group, editors. Drug safety - a shared responsibility. New York (NY): Churchill Livingstone, 1991; 38 Talbot JC. Spontaneous reporting. In: Glaxo Research Group, editors. Drug safety - a shared responsibility. New York (NY): Churchill Livingstone, 1991; 38
13.
go back to reference Ferguson M, Dhillon S. A survey of adverse drug reaction reporting by hospital pharmacists to the committee on safety of medicines — the role of pharmacy departments. Int J Pharm Pract 1999; 7(3): 167–71CrossRef Ferguson M, Dhillon S. A survey of adverse drug reaction reporting by hospital pharmacists to the committee on safety of medicines — the role of pharmacy departments. Int J Pharm Pract 1999; 7(3): 167–71CrossRef
14.
go back to reference Committee on Safety of Medicines, Medicines Control Agency. Pharmacovigilance — the Yellow Card Scheme. Information pack for pharmacists, 1997 Committee on Safety of Medicines, Medicines Control Agency. Pharmacovigilance — the Yellow Card Scheme. Information pack for pharmacists, 1997
15.
go back to reference Anonymous. Yellow card reporting - how far have we come? Hosp Pharm 2000; 7: 103–6 Anonymous. Yellow card reporting - how far have we come? Hosp Pharm 2000; 7: 103–6
16.
go back to reference Green CF, Mottram DR, Pimohamed M, et al. A record year for the ‘green card’ adverse drug reaction reporting scheme. UKCPA Symposium. An investigation into adverse drug reaction reporting by hospital pharmacy departments in the United Kingdom. 1997 Nov 21, Blackpool Green CF, Mottram DR, Pimohamed M, et al. A record year for the ‘green card’ adverse drug reaction reporting scheme. UKCPA Symposium. An investigation into adverse drug reaction reporting by hospital pharmacy departments in the United Kingdom. 1997 Nov 21, Blackpool
Metadata
Title
A Survey on Factors that Could Affect Adverse Drug Reaction Reporting According to Hospital Pharmacists in Great Britain
Authors
Dimah Sweis
Dr Ian C.K. Wong
Publication date
01-08-2000
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 2/2000
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200023020-00006

Other articles of this Issue 2/2000

Drug Safety 2/2000 Go to the issue